Table 1 Demographic and baseline characteristics of the subjects who received 1 mg (Group A) or 0.5 mg (Group B) of NeuroEPO every 8 h, during 4 days, by nasal route
Characteristic | Group A N = 12 | Group B N = 13 | Total N = 25 |
|---|---|---|---|
Female gender | 7 (58.3%) | 7 (53.8%) | 14 (56.0%) |
Skin color | |||
White | 7 (58.3%) | 6 (46.2%) | 13 (52.0%) |
Non-white | 5 (41.7%) | 7 (53.8%) | 12 (48.0%) |
Age (years) | 28 ± 6 | 26 ± 4 | 27 ± 5 |
Weight (Kg) | 67 ± 13 | 63 ± 10 | 65 ± 11 |
Height (cm) | 164 ± 9 | 169 ± 11 | 167 ± 10 |